Vani Vannappagari

2.2k total citations · 1 hit paper
71 papers, 1.3k citations indexed

About

Vani Vannappagari is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Vani Vannappagari has authored 71 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Infectious Diseases, 24 papers in Virology and 19 papers in Epidemiology. Recurrent topics in Vani Vannappagari's work include HIV/AIDS Research and Interventions (48 papers), HIV/AIDS drug development and treatment (38 papers) and HIV Research and Treatment (24 papers). Vani Vannappagari is often cited by papers focused on HIV/AIDS Research and Interventions (48 papers), HIV/AIDS drug development and treatment (38 papers) and HIV Research and Treatment (24 papers). Vani Vannappagari collaborates with scholars based in United States, United Kingdom and South Africa. Vani Vannappagari's co-authors include Ella T. Nkhoma, Susan A. Hall, Ernest Beutler, Charles Poole, William A. Blumentals, Andres Gomez‐Caminero, Sung Joo, Jennifer S Fusco, Gregory Fusco and Laurence Brunet and has published in prestigious journals such as PLoS ONE, Obstetrics and Gynecology and AIDS.

In The Last Decade

Vani Vannappagari

62 papers receiving 1.2k citations

Hit Papers

The global prevalence of glucose-6-phosphate dehydrogenas... 2009 2026 2014 2020 2009 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis
    2009 495 citations Vani Vannappagari et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vani Vannappagari United States 14 423 418 228 209 190 71 1.3k
Sohail Rana United States 30 561 1.3× 348 0.8× 121 0.5× 120 0.6× 158 0.8× 77 2.6k
M Vial France 17 219 0.5× 351 0.8× 142 0.6× 222 1.1× 295 1.6× 59 1.1k
Véronique Schiffer Netherlands 16 114 0.3× 613 1.5× 109 0.5× 663 3.2× 290 1.5× 43 1.2k
Anju Seth India 19 271 0.6× 148 0.4× 116 0.5× 20 0.1× 156 0.8× 114 1.3k
Paul Telfer United Kingdom 30 827 2.0× 302 0.7× 93 0.4× 78 0.4× 806 4.2× 98 3.4k
Juliana Meyers United States 20 46 0.1× 396 0.9× 55 0.2× 96 0.5× 374 2.0× 56 1.2k
Philip Grant United States 20 50 0.1× 1.4k 3.4× 115 0.5× 407 1.9× 466 2.5× 61 2.5k
Robert Leduc United States 21 275 0.7× 184 0.4× 137 0.6× 88 0.4× 178 0.9× 36 1.6k
Wolfgang Stöhr United Kingdom 22 233 0.6× 889 2.1× 165 0.7× 691 3.3× 282 1.5× 65 1.6k
Pamela Tropper United States 16 484 1.1× 269 0.6× 202 0.9× 256 1.2× 185 1.0× 35 1.3k

Countries citing papers authored by Vani Vannappagari

Since Specialization
Citations

This map shows the geographic impact of Vani Vannappagari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vani Vannappagari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vani Vannappagari more than expected).

Fields of papers citing papers by Vani Vannappagari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vani Vannappagari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vani Vannappagari. The network helps show where Vani Vannappagari may publish in the future.

Co-authorship network of co-authors of Vani Vannappagari

This figure shows the co-authorship network connecting the top 25 collaborators of Vani Vannappagari. A scholar is included among the top collaborators of Vani Vannappagari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vani Vannappagari. Vani Vannappagari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anderson, Kim, Helena Rabie, Brian Eley, et al.. (2025). Mother‐child dyads living with HIV in the Western Cape, South Africa: Undetectable = Undetectable?. Journal of the International AIDS Society. 28(2). e26418–e26418.
2.
Brunet, Laurence, Gerald Pierone, Brooke Levis, et al.. (2024). Immunological and virological response to fostemsavir in routine US clinical care: An OPERA cohort study. HIV Medicine. 26(1). 17–25.
3.
Short, William R., et al.. (2024). Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review. Infectious Diseases and Therapy. 14(1). 59–80.
4.
Albano, Jessica D., Angela E. Scheuerle, D. Heather Watts, et al.. (2024). The Antiretroviral Pregnancy Registry: Three decades of prospective monitoring for birth defects. Pharmacoepidemiology and Drug Safety. 33(6). e5801–e5801. 2 indexed citations
5.
Pierone, Gerald, Jennifer S Fusco, Laurence Brunet, et al.. (2024). Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States. AIDS Research and Therapy. 21(1). 76–76. 1 indexed citations
6.
İşlek, Duygu, Travis Sanchez, Jennifer L. Glick, et al.. (2024). Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study. JMIR Public Health and Surveillance. 10. e62801–e62801. 4 indexed citations
7.
8.
9.
Sension, Michael, Laurence Brunet, Jennifer S Fusco, et al.. (2023). Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort. Infectious Diseases and Therapy. 12(12). 2807–2817. 30 indexed citations
10.
Fusco, Jennifer S, Cassidy Henegar, Vani Vannappagari, et al.. (2023). Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes. BMC Infectious Diseases. 23(1). 91–91. 5 indexed citations
11.
Sension, Michael, Jennifer S Fusco, Laurence Brunet, et al.. (2023). 1608. Real-World Effectiveness of Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Treatment-Experienced Individuals: Two Years of Data from the OPERA® Cohort. Open Forum Infectious Diseases. 10(Supplement_2). 7 indexed citations
12.
Beckham, S. Wilson, Travis Sanchez, María Zlotorzynska, et al.. (2023). Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis. AIDS Patient Care and STDs. 37(10). 495–503. 8 indexed citations
13.
Pierone, Gerald, Jennifer S Fusco, Vani Vannappagari, et al.. (2022). Dolutegravir/rilpivirine 2-drug regimen comparable to commonly prescribed 3-drug regimens up to 18-months in a real-world setting. Antiviral Therapy. 27(1). 2 indexed citations
14.
Mounzer, Karam, Jennifer S Fusco, Laurence Brunet, et al.. (2021). Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort. AIDS Patient Care and STDs. 35(11). 419–427. 7 indexed citations
15.
Mounzer, Karam, Laurence Brunet, Ricky Hsu, et al.. (2021). Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States. AIDS Research and Human Retroviruses. 37(11). 852–861. 11 indexed citations
16.
Mounzer, Karam, Laurence Brunet, Ricky Hsu, et al.. (2019). 978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV. Open Forum Infectious Diseases. 6(Supplement_2). S36–S37. 9 indexed citations
17.
Fusco, Jennifer S, Cassidy Henegar, E. Byrd Quinlivan, et al.. (2019). Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort. Current HIV Research. 17(4). 266–276. 1 indexed citations
18.
Hsu, Ricky, Jennifer S Fusco, Cassidy Henegar, et al.. (2018). Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database. Therapeutic Advances in Drug Safety. 9(12). 675–686. 7 indexed citations
19.
Chulada, Patricia C., Linda A. Corey, Vani Vannappagari, Nedra Whitehead, & Perry J. Blackshear. (2006). The Feasibility of Creating a Population-Based National Twin Registry in the United States. Twin Research and Human Genetics. 9(6). 919–926. 2 indexed citations
20.
Chulada, Patricia C., Linda A. Corey, Vani Vannappagari, Nedra Whitehead, & Perry J. Blackshear. (2006). The Feasibility of Creating a Population-Based National Twin Registry in the United States. Twin Research and Human Genetics. 9(6). 919–926. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sohail Rana Breakdown of academic impact, for papers by M Vial Breakdown of academic impact, for papers by Véronique Schiffer Breakdown of academic impact, for papers by Anju Seth Breakdown of academic impact, for papers by Paul Telfer Breakdown of academic impact, for papers by Juliana Meyers Breakdown of academic impact, for papers by Philip Grant Breakdown of academic impact, for papers by Robert Leduc Breakdown of academic impact, for papers by Wolfgang Stöhr Breakdown of academic impact, for papers by Pamela Tropper
Rankless by CCL
2026